| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
55,020,000 |
| Market
Cap: |
4.62(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.084 - $0.084 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for woman's reproductive health and pregnancy. Co.'s portfolio includes: Linzagolix, which is an oral gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis in pre-menopausal women; Ebopiprant, which is an oral selective prostaglandin F2a, receptor antagonist, treatment for preterm labor; and Nolasiban, which improves clinical pregnancy and live birth rates in women undergoing embryo transfer following an in-vitro fertilization cycle.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
8,000,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$820,000 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Loumaye Ernest |
Director |
– • – |
2023-04-06 |
4 |
B |
$0.10 |
$380,000 |
D/D |
4,000,000 |
10,000,000 |
2.39 |
-9% |
|
| Loumaye Ernest |
Director |
– • – |
2023-02-28 |
4 |
B |
$0.11 |
$440,000 |
D/D |
4,000,000 |
6,000,000 |
2.39 |
-39% |
|
| Loumaye Ernest |
Director |
– • – |
2023-01-01 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
2,000,000 |
|
- |
|
| Loumaye Ernest |
Director |
– • – |
2023-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,999,827 |
|
-46% |
|
| Clancy Annette |
Director |
– • – |
2023-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
97,500 |
|
-46% |
|
5 Records found
|
1
|
Page 1 of 1 |
|
|
